Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Metabolomics Profile and 10-Year Atherosclerotic Cardiovascular Disease (Ascvd) Risk Score Publisher



Dehghanbanadaki H1 ; Dodangeh S1 ; Parhizkarroudsari P2 ; Hosseinkhani S3 ; Khashayar P4 ; Noorchenarboo M5 ; Rezaei N6 ; Dilmaghanimarand A6 ; Yoosefi M6 ; Arjmand B7 ; Khalagi K8, 9 ; Najjar N10 ; Kakaei A9 ; Bandarian F10 Show All Authors
Authors
  1. Dehghanbanadaki H1
  2. Dodangeh S1
  3. Parhizkarroudsari P2
  4. Hosseinkhani S3
  5. Khashayar P4
  6. Noorchenarboo M5
  7. Rezaei N6
  8. Dilmaghanimarand A6
  9. Yoosefi M6
  10. Arjmand B7
  11. Khalagi K8, 9
  12. Najjar N10
  13. Kakaei A9
  14. Bandarian F10
  15. Aghaei Meybodi H11
  16. Larijani B1
  17. Razi F10
Show Affiliations
Authors Affiliations
  1. 1. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular, Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
  5. 5. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran, Iran
  8. 8. Obesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  9. 9. Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  10. 10. Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  11. 11. Personalized Medicine Research 10-Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Frontiers in Cardiovascular Medicine Published:2023


Abstract

Background: The intermediate metabolites associated with the development of atherosclerotic cardiovascular disease (ASCVD) remain largely unknown. Thus, we conducted a large panel of metabolomics profiling to identify the new candidate metabolites that were associated with 10-year ASCVD risk. Methods: Thirty acylcarnitines and twenty amino acids were measured in the fasting plasma of 1,102 randomly selected individuals using a targeted FIA-MS/MS approach. The 10-year ASCVD risk score was calculated based on 2013 ACC/AHA guidelines. Accordingly, the subjects were stratified into four groups: low-risk (n = 620), borderline-risk (n = 110), intermediate-risk (n = 225), and high-risk (n = 147). 10 factors comprising collinear metabolites were extracted from principal component analysis. Results: C4DC, C8:1, C16OH, citrulline, histidine, alanine, threonine, glycine, glutamine, tryptophan, phenylalanine, glutamic acid, arginine, and aspartic acid were significantly associated with the 10-year ASCVD risk score (p-values ≤ 0.044). The high-risk group had higher odds of factor 1 (12 long-chain acylcarnitines, OR = 1.103), factor 2 (5 medium-chain acylcarnitines, OR = 1.063), factor 3 (methionine, leucine, valine, tryptophan, tyrosine, phenylalanine, OR = 1.074), factor 5 (6 short-chain acylcarnitines, OR = 1.205), factor 6 (5 short-chain acylcarnitines, OR = 1.229), factor 7 (alanine, proline, OR = 1.343), factor 8 (C18:2OH, glutamic acid, aspartic acid, OR = 1.188), and factor 10 (ornithine, citrulline, OR = 1.570) compared to the low-risk ones; the odds of factor 9 (glycine, serine, threonine, OR = 0.741), however, were lower in the high-risk group. “D-glutamine and D-glutamate metabolism”, “phenylalanine, tyrosine, and tryptophan biosynthesis”, and “valine, leucine, and isoleucine biosynthesis” were metabolic pathways having the highest association with borderline/intermediate/high ASCVD events, respectively. Conclusions: Abundant metabolites were found to be associated with ASCVD events in this study. Utilization of this metabolic panel could be a promising strategy for early detection and prevention of ASCVD events. 2023 Dehghanbanadaki, Dodangeh, Parhizkar Roudsari, Hosseinkhani, Khashayar, Noorchenarboo, Rezaei, Dilmaghani-Marand, Yoosefi, Arjmand, Khalagi, Najjar, Kakaei, Bandarian, Aghaei Meybodi, Larijani and Razi.